Vericel Corporation Logo

Vericel Corporation

VCEL

(1.5)
Stock Price

56,50 USD

0.21% ROA

1.48% ROE

2551.54x PER

Market Cap.

2.027.398.770,00 USD

39.34% DER

0% Yield

1.56% NPM

Vericel Corporation Stock Analysis

Vericel Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vericel Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (42%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 ROE

Negative ROE (-6.3%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-3.96%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 PBV

The stock's elevated P/BV ratio (8.75x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-60) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Vericel Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vericel Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Vericel Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vericel Corporation Revenue
Year Revenue Growth
1996 1.600.000
1997 400.000 -300%
1998 249.000 -60.64%
1999 881.000 71.74%
2000 1.150.000 23.39%
2001 899.000 -27.92%
2002 877.000 -2.51%
2003 844.000 -3.91%
2004 1.302.000 35.18%
2005 909.000 -43.23%
2006 863.000 -5.33%
2007 685.000 -25.99%
2008 522.000 -31.23%
2009 182.000 -186.81%
2010 89.000 -104.49%
2011 18.000 -394.44%
2012 21.000 14.29%
2013 19.000 -10.53%
2014 28.796.000 99.93%
2015 51.168.000 43.72%
2016 54.383.000 5.91%
2017 63.924.000 14.93%
2018 90.857.000 29.64%
2019 117.850.000 22.9%
2020 124.179.000 5.1%
2021 156.184.000 20.49%
2022 164.365.000 4.98%
2023 182.324.000 9.85%
2023 197.516.000 7.69%
2024 210.648.000 6.23%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vericel Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 13.400.000 100%
1998 15.498.000 13.54%
1999 10.871.000 -42.56%
2000 6.289.000 -72.86%
2001 4.983.000 -26.21%
2002 5.428.000 8.2%
2003 5.647.000 3.88%
2004 6.289.000 10.21%
2005 7.206.000 12.73%
2006 9.484.000 24.02%
2007 11.443.000 17.12%
2008 15.249.000 24.96%
2009 11.289.000 -35.08%
2010 12.658.000 10.82%
2011 21.330.000 40.66%
2012 26.025.000 18.04%
2013 15.104.000 -72.31%
2014 21.263.000 28.97%
2015 18.890.000 -12.56%
2016 15.295.000 -23.5%
2017 12.944.000 -18.16%
2018 13.599.000 4.82%
2019 30.391.000 55.25%
2020 13.020.000 -133.42%
2021 16.287.000 20.06%
2022 19.943.000 18.33%
2023 22.704.000 12.16%
2023 21.042.000 -7.9%
2024 29.452.000 28.55%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vericel Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 2.000.000 100%
1998 2.858.000 30.02%
1999 2.836.000 -0.78%
2000 3.364.000 15.7%
2001 2.482.000 -35.54%
2002 3.528.000 29.65%
2003 4.017.000 12.17%
2004 5.390.000 25.47%
2005 5.972.000 9.75%
2006 9.101.000 34.38%
2007 8.682.000 -4.83%
2008 6.436.000 -34.9%
2009 4.950.000 -30.02%
2010 5.201.000 4.83%
2011 0 0%
2012 7.750.000 100%
2013 5.875.000 -31.91%
2014 13.774.000 57.35%
2015 22.479.000 38.73%
2016 27.388.000 17.92%
2017 35.610.000 23.09%
2018 49.007.000 27.34%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vericel Corporation EBITDA
Year EBITDA Growth
1996 -10.800.000
1997 -15.200.000 28.95%
1998 -17.730.000 14.27%
1999 -13.843.000 -28.08%
2000 -9.429.000 -46.81%
2001 -6.477.000 -45.58%
2002 -8.155.000 20.58%
2003 -9.594.000 15%
2004 -10.532.000 8.91%
2005 -12.330.000 14.58%
2006 -17.542.000 29.71%
2007 -19.469.000 9.9%
2008 -20.868.000 6.7%
2009 -15.465.000 -34.94%
2010 -17.212.000 10.15%
2011 -37.722.000 54.37%
2012 -33.061.000 -14.1%
2013 -20.459.000 -61.6%
2014 -23.512.000 12.98%
2015 -16.588.000 -41.74%
2016 -16.609.000 0.13%
2017 -15.062.000 -10.27%
2018 -3.043.000 -394.97%
2019 -9.657.000 68.49%
2020 3.050.000 416.62%
2021 -7.578.000 140.25%
2022 -15.622.000 51.49%
2023 -10.568.000 -47.82%
2023 -1.832.000 -476.86%
2024 -18.832.000 90.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vericel Corporation Gross Profit
Year Gross Profit Growth
1996 -8.000.000
1997 900.000 988.89%
1998 249.000 -261.45%
1999 875.000 71.54%
2000 224.000 -290.63%
2001 886.000 74.72%
2002 675.000 -31.26%
2003 -49.000 1477.55%
2004 1.022.000 104.79%
2005 761.000 -34.3%
2006 852.000 10.68%
2007 656.000 -29.88%
2008 466.000 -40.77%
2009 70.000 -565.71%
2010 55.000 -27.27%
2011 14.000 -292.86%
2012 15.000 6.67%
2013 15.000 0%
2014 11.503.000 99.87%
2015 24.698.000 53.43%
2016 26.076.000 5.28%
2017 33.570.000 22.32%
2018 58.697.000 42.81%
2019 80.279.000 26.88%
2020 84.228.000 4.69%
2021 106.025.000 20.56%
2022 109.788.000 3.43%
2023 122.432.000 10.33%
2023 135.576.000 9.69%
2024 146.404.000 7.4%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vericel Corporation Net Profit
Year Net Profit Growth
1996 -9.900.000
1997 -14.300.000 30.77%
1998 -17.233.000 17.02%
1999 -11.028.000 -56.27%
2000 -9.390.000 -17.44%
2001 -5.926.000 -58.45%
2002 -7.939.000 25.36%
2003 -9.579.000 17.12%
2004 -10.488.000 8.67%
2005 -11.811.000 11.2%
2006 -16.475.000 28.31%
2007 -17.594.000 6.36%
2008 -20.133.000 12.61%
2009 -15.946.000 -26.26%
2010 -17.729.000 10.06%
2011 -19.668.000 9.86%
2012 -29.474.000 33.27%
2013 -15.622.000 -88.67%
2014 -19.920.000 21.58%
2015 -16.340.000 -21.91%
2016 -19.566.000 16.49%
2017 -17.286.000 -13.19%
2018 -8.137.000 -112.44%
2019 -7.909.000 -2.88%
2020 2.864.000 376.15%
2021 -7.471.000 138.33%
2022 -16.709.000 55.29%
2023 -14.640.000 -14.13%
2023 -3.182.000 -360.09%
2024 -18.728.000 83.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vericel Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -171
1997 -203 15.76%
1998 -206 1.46%
1999 -115 -79.13%
2000 -64 -79.69%
2001 -28 -137.04%
2002 -30 10%
2003 -30 0%
2004 -23 -36.36%
2005 -20 -10%
2006 -25 16.67%
2007 -24 -4.35%
2008 -25 4.17%
2009 -18 -41.18%
2010 -14 -21.43%
2011 -10 -40%
2012 -14 28.57%
2013 -5 -180%
2014 -2 -400%
2015 -1 0%
2016 -1 0%
2017 -1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vericel Corporation Free Cashflow
Year Free Cashflow Growth
1996 -9.500.000
1997 -13.700.000 30.66%
1998 -15.873.000 13.69%
1999 -11.271.000 -40.83%
2000 -7.013.000 -60.72%
2001 -6.420.000 -9.24%
2002 -8.902.000 27.88%
2003 -9.109.000 2.27%
2004 -9.682.000 5.92%
2005 -11.651.000 16.9%
2006 -14.307.000 18.56%
2007 -15.890.000 9.96%
2008 -19.742.000 19.51%
2009 -13.840.000 -42.64%
2010 -15.205.000 8.98%
2011 -25.523.000 40.43%
2012 -29.818.000 14.4%
2013 -19.983.000 -49.22%
2014 -26.239.000 23.84%
2015 -15.773.000 -66.35%
2016 -21.307.000 25.97%
2017 -14.693.000 -45.01%
2018 -3.090.000 -375.5%
2019 -9.799.000 68.47%
2020 14.946.000 165.56%
2021 21.125.000 29.25%
2022 10.091.000 -109.34%
2023 600.000 -1581.83%
2023 7.798.000 92.31%
2024 1.774.000 -339.57%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vericel Corporation Operating Cashflow
Year Operating Cashflow Growth
1996 -9.100.000
1997 -13.300.000 31.58%
1998 -15.639.000 14.96%
1999 -11.198.000 -39.66%
2000 -6.877.000 -62.83%
2001 -6.362.000 -8.09%
2002 -8.749.000 27.28%
2003 -8.990.000 2.68%
2004 -9.525.000 5.62%
2005 -11.065.000 13.92%
2006 -13.518.000 18.15%
2007 -14.826.000 8.82%
2008 -19.527.000 24.07%
2009 -13.805.000 -41.45%
2010 -15.085.000 8.49%
2011 -24.492.000 38.41%
2012 -29.545.000 17.1%
2013 -19.943.000 -48.15%
2014 -25.410.000 21.52%
2015 -13.346.000 -90.39%
2016 -19.892.000 32.91%
2017 -13.183.000 -50.89%
2018 -412.000 -3099.76%
2019 -7.183.000 94.26%
2020 17.572.000 140.88%
2021 29.040.000 39.49%
2022 17.687.000 -64.19%
2023 7.169.000 -146.72%
2023 35.311.000 79.7%
2024 18.535.000 -90.51%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vericel Corporation Capital Expenditure
Year Capital Expenditure Growth
1996 400.000
1997 400.000 0%
1998 234.000 -70.94%
1999 73.000 -220.55%
2000 136.000 46.32%
2001 58.000 -134.48%
2002 153.000 62.09%
2003 119.000 -28.57%
2004 157.000 24.2%
2005 586.000 73.21%
2006 789.000 25.73%
2007 1.064.000 25.85%
2008 215.000 -394.88%
2009 35.000 -514.29%
2010 120.000 70.83%
2011 1.031.000 88.36%
2012 273.000 -277.66%
2013 40.000 -582.5%
2014 829.000 95.17%
2015 2.427.000 65.84%
2016 1.415.000 -71.52%
2017 1.510.000 6.29%
2018 2.678.000 43.61%
2019 2.616.000 -2.37%
2020 2.626.000 0.38%
2021 7.915.000 66.82%
2022 7.596.000 -4.2%
2023 6.569.000 -15.63%
2023 27.513.000 76.12%
2024 16.761.000 -64.15%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vericel Corporation Equity
Year Equity Growth
1996 -23.400.000
1997 16.600.000 240.96%
1998 10.846.000 -53.05%
1999 8.511.000 -27.44%
2000 12.435.000 31.56%
2001 10.894.000 -14.15%
2002 10.803.000 -0.84%
2003 11.575.000 6.67%
2004 17.608.000 34.26%
2005 33.028.000 46.69%
2006 42.342.000 22%
2007 28.251.000 -49.88%
2008 23.334.000 -21.07%
2009 17.284.000 -35%
2009 17.284.000 0%
2010 2.922.000 -491.51%
2011 -12.971.000 122.53%
2012 9.513.000 236.35%
2013 3.894.000 -144.3%
2014 35.641.000 89.07%
2015 22.130.000 -61.05%
2016 24.709.000 10.44%
2017 22.540.000 -9.62%
2018 102.231.000 77.95%
2019 111.091.000 7.98%
2020 134.260.000 17.26%
2021 170.462.000 21.24%
2022 192.272.000 11.34%
2023 204.380.000 5.92%
2023 225.952.000 9.55%
2024 242.977.000 7.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vericel Corporation Assets
Year Assets Growth
1996 12.700.000
1997 18.400.000 30.98%
1998 12.374.000 -48.7%
1999 9.540.000 -29.71%
2000 13.437.000 29%
2001 11.905.000 -12.87%
2002 11.553.000 -3.05%
2003 12.155.000 4.95%
2004 18.166.000 33.09%
2005 33.897.000 46.41%
2006 44.881.000 24.47%
2007 32.848.000 -36.63%
2008 26.217.000 -25.29%
2009 19.276.000 -36.01%
2009 19.276.000 0%
2010 32.827.000 41.28%
2011 7.739.000 -324.18%
2012 15.178.000 49.01%
2013 9.215.000 -64.71%
2014 47.579.000 80.63%
2015 34.309.000 -38.68%
2016 48.598.000 29.4%
2017 54.577.000 10.96%
2018 118.689.000 54.02%
2019 153.238.000 22.55%
2020 205.608.000 25.47%
2021 243.705.000 15.63%
2022 273.003.000 10.73%
2023 318.125.000 14.18%
2023 353.657.000 10.05%
2024 376.839.000 6.15%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vericel Corporation Liabilities
Year Liabilities Growth
1996 36.100.000
1997 1.800.000 -1905.56%
1998 1.528.000 -17.8%
1999 1.029.000 -48.49%
2000 1.002.000 -2.69%
2001 1.011.000 0.89%
2002 750.000 -34.8%
2003 580.000 -29.31%
2004 558.000 -3.94%
2005 869.000 35.79%
2006 2.539.000 65.77%
2007 4.597.000 44.77%
2008 2.883.000 -59.45%
2009 1.992.000 -44.73%
2009 1.992.000 0%
2010 29.905.000 93.34%
2011 20.710.000 -44.4%
2012 5.665.000 -265.58%
2013 5.321.000 -6.46%
2014 11.938.000 55.43%
2015 12.179.000 1.98%
2016 23.889.000 49.02%
2017 32.037.000 25.43%
2018 16.458.000 -94.66%
2019 42.147.000 60.95%
2020 71.348.000 40.93%
2021 73.243.000 2.59%
2022 80.731.000 9.28%
2023 113.745.000 29.02%
2023 127.705.000 10.93%
2024 133.862.000 4.6%

Vericel Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.41
Net Income per Share
0.02
Price to Earning Ratio
2551.54x
Price To Sales Ratio
9.45x
POCF Ratio
46.83
PFCF Ratio
-925.75
Price to Book Ratio
8.29
EV to Sales
9.54
EV Over EBITDA
837.7
EV to Operating CashFlow
47.62
EV to FreeCashFlow
-934.86
Earnings Yield
0
FreeCashFlow Yield
-0
Market Cap
2,03 Bil.
Enterprise Value
2,05 Bil.
Graham Number
1.35
Graham NetNet
0.77

Income Statement Metrics

Net Income per Share
0.02
Income Quality
54.49
ROE
0
Return On Assets
0.01
Return On Capital Employed
-0
Net Income per EBT
0.76
EBT Per Ebit
-3.78
Ebit per Revenue
-0.01
Effective Tax Rate
0.52

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.11
Stock Based Compensation to Revenue
0.16
Gross Profit Margin
0.71
Operating Profit Margin
-0.01
Pretax Profit Margin
0.02
Net Profit Margin
0.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.88
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
1.05
Capex to Revenue
0.21
Capex to Depreciation
9.03
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
81.66
Days Payables Outstanding
145.06
Days of Inventory on Hand
85.64
Receivables Turnover
4.47
Payables Turnover
2.52
Inventory Turnover
4.26
Capex per Share
0.93

Balance Sheet

Cash per Share
2,63
Book Value per Share
4,99
Tangible Book Value per Share
4.86
Shareholders Equity per Share
4.99
Interest Debt per Share
1.98
Debt to Equity
0.39
Debt to Assets
0.25
Net Debt to EBITDA
8.16
Current Ratio
4.5
Tangible Asset Value
0,24 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
306192000
Working Capital
0,15 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,05 Bil.
Average Payables
0,02 Bil.
Average Inventory
14222000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vericel Corporation Dividends
Year Dividends Growth

Vericel Corporation Profile

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

CEO
Mr. Dominick C. Colangelo Esq.
Employee
314
Address
64 Sidney Street
Cambridge, 02139

Vericel Corporation Executives & BODs

Vericel Corporation Executives & BODs
# Name Age
1 Mr. Dominick C. Colangelo Esq.
Chief Executive Officer, President & Director
70
2 Mr. Jonathan D. Siegal
Principal Accounting Officer, Vice President & Corporate Controller
70
3 Mr. Patrick Helfrich
Vice President of Marketing & Commercial Strategy
70
4 Mr. Eric Burns
Vice President of Finance & Investor Relations
70
5 Mr. Michael Halpin
Chief Operating Officer
70
6 Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.
Chief Medical Officer
70
7 Mr. Mike Gilligan
Senior Vice President of Sales
70
8 Mr. Patrick J. Fowler
Senior Vice President of Corporate Development & Strategy
70
9 Mr. Sean C. Flynn
Chief Legal Officer
70
10 Mr. Joseph Anthony Mara Jr.
Chief Financial Officer & Treasurer
70

Vericel Corporation Competitors